@article{aa5390293c7141319999cd183286828f,
title = "Thyroid Gland Malignancies",
keywords = "Anaplastic, Cabozantinib, Differentiated, Lenvatinib, Medullary, Sorafenib, Thyroid cancer, Vandetanib",
author = "Cabanillas, {Maria E.} and Ramona Dadu and Hu, {Mimi I.} and Charles Lu and Gunn, {Gary Brandon} and Grubbs, {Elizabeth G.} and Lai, {Stephen Y.} and Williams, {Michelle D.}",
note = "Funding Information: Disclosures: M.E. Cabanillas has received grant funding from Eisai , Exelixis , and Roche . M.E. Cabanillas has received consultant fees from AstraZeneca , Exelixis, Eisai, and Bayer . M.I. Hu has received grant funding from AstraZeneca. R. Dadu, C. Lu, G.B. Gunn, E.G. Grubbs, S.Y. Lai, and M.D. Williams have nothing to disclose. ",
year = "2015",
month = dec,
doi = "10.1016/j.hoc.2015.07.011",
language = "English (US)",
volume = "29",
pages = "1123--1143",
journal = "Hematology/Oncology Clinics of North America",
issn = "0889-8588",
publisher = "W.B. Saunders Ltd",
number = "6",
}